Because the Goldman's leech started to talk yesterday. Last one or two years are very good time for biotech. A lot of biotech companies doubled or tripled without solid good news. We had better science and better news on the trial front, and our share price has been cut more than half. Let him go, let's cure our Goldman's anemia. When will be the voting day? Stand up together, let's vote him out.
To-day's drop was most probably the manipulation of day-trading monkeys by the market maker to help accumulation by his institutional buddies. Institutions were not sellers to-day! In any case, a gradual uptrend will resume to-morrow.
How about replacing MM with J. Scott Garland? April we will vote again.
Since we are focusing on cabo phase III trials and marketing, research in chemistry(screening candidate chemicals) is far out of scope. This two year's history proved it all, not good at dealing with FDA and finance. Expertise in putting the drug on market is more important from now on.
He joined Exelixis from Genentech, where, from 2009 to 2011, he served as vice president of the Avastin franchise. From 2007 to 2009, Mr. Garland served as vice president, hematology marketing and sales at Genentech, overseeing the Rituxan franchise, and from 2002 to 2007 served in other positions of increasing responsibility at Genentech. Before joining Genentech, Mr. Garland served in positions of increasing responsibility at Amgen and Merck.